TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03405207
Drug: Vitamin D3 50000 UNT Oral Capsule
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Holick's protocol of treating vitamin D deficiency lasting for 8 weeks
Study: NCT00834041
Drug: Aliskiren 3.125 mini-tablets
DrugBank: Aliskiren (DB09026)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral mini-tablets (3.125 mg) of aliskiren once each morning
Study: NCT02888054
Drug: lesinurad/allopurinol 200/300 FDC tablet
DrugBank: Allopurinol (DB00437)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02888054
Drug: lesinurad 200 mg
Normalized name: lesinurad 200 MG
DrugBank: Lesinurad (DB11560)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02888054
Drug: allopurinol 300 mg
Normalized name: allopurinol 300 MG
DrugBank: Allopurinol (DB00437)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04005768
Drug: Hydroxychloroquine Sulphate
Normalized name: Hydroxychloroquine sulphate
DrugBank: Hydroxychloroquine (DB01611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: After a stabilization period of 20 min and 10 min after the first blood collection, Plaquenil (Hydroxychloroquine sulfate) will be administered per os (total dose of 400 mg) in a randomized, double-blinded fashion.
Study: NCT00367926
Drug: American ginseng root / polysaccharides
DrugBank: Ginseng (DB01404)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01866254
Drug: Hydromorphone
Normalized name: Hydromorphone
DrugBank: Hydromorphone (DB00327)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Injection of 100 mcg hydromorphone into the intrathecal space
Study: NCT01866254
Drug: Morphine
Normalized name: Morphine
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Injection of 200 mcg of intrathecal morphine
Study: NCT00779740
Drug: mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The dose will be 50 mcg as MF in one spray (100 µL) per nostril two times a day (morning and night) for 2 weeks. The daily dose of MF will be 200 mcg.
Study: NCT00779740
Drug: mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The dose will be 50 mcg as MF in one spray (50 µL) per nostril two times a day (morning and night) for 2 weeks. The daily dose of MF will be 200 mcg.
Study: NCT03557853
Drug: Golimumab Injection
Normalized name: golimumab Injection
DrugBank: Golimumab (DB06674)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Simponi (golimumab) in fixed dose of 50 mg sc per month according to local label and local clinical practice.
Study: NCT01058655
Drug: Everolimus
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT01058655
Drug: Tivozanib
Normalized name: Tivozanib
DrugBank: Tivozanib (DB11800)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02154074
Drug: Isoflurane
Normalized name: Isoflurane
DrugBank: Isoflurane (DB00753)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: inhale Isoflurane 1.5MAC
Study: NCT02154074
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: anesthesia induction period: intravenous pumping Dexmedetomidine 4ug/Kg/h; after 10 minutes,turn to 0.4ug/Kg/h.
Study: NCT01172522
Drug: Fexofenadine
Normalized name: Fexofenadine
DrugBank: Fexofenadine (DB00950)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fexofenadine 1%
Study: NCT04537429
Drug: Eptinezumab
Normalized name: Eptinezumab
DrugBank: Eptinezumab (DB14040)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: up to four iv infusions of eptinezumab
Study: NCT00003052
Drug: etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00003052
Drug: ifosfamide
Normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03060005
Drug: Tears Naturale Forte
Normalized name: Tears Naturale Forte
DrugBank: Dextran (DB09255)
Approvals — FDA: no, EMA: no, PMDA: no
Description: This medication is used to relieve dry, irritated eyes
Study: NCT03060005
Drug: liposic
Normalized name: Lipoic acid
DrugBank: Lipoic acid (DB00166)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liposic eye gel contain the active ingredient carbomer, which is a type of medicine known as an eye lubricant. It is used for the treatment of the symptoms of dry eye.
Study: NCT00884442
Drug: Nifedipine (Gen-nifedipine extended release, previously referred to as Gen-Nifedipine XL)
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 60 mg nifedipine
Study: NCT00884442
Drug: Nifedipine (Bayer Healthcare AG manufactured as Adalat® XL®, Adalat® LA, Adalat® Crono, Adalat® OROS)
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 60 mg nifedipine
Study: NCT00623103
Drug: Rivastigmine capsule
Normalized name: Rivastigmine
DrugBank: Rivastigmine (DB00989)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Rivastigmine capsules orally twice a day. Target dose 12 mg/day.
Study: NCT00623103
Drug: Rivastigmine transdermal patch
Normalized name: rivastigmine Transdermal Product
DrugBank: Rivastigmine (DB00989)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Rivastigmine patch once a day in the morning, worn for 24 hours. Target dose 10 cm\^2/day delivering 9.5 mg over a 24 hour period.
Study: NCT03146377
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 85 mg/m2 IV on day 1 of a 2-week cycle
Study: NCT03146377
Drug: Irinotecan
Normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 165 mg/m2 IV on day 1 of a 2-week cycle
Study: NCT04569656
Drug: hydrolyzed guar gum
Normalized name: Partially Hydrolyzed Guar Gum Oral Powder for Suspension
DrugBank: Guar gum (DB13446)
Approvals — FDA: no, EMA: no, PMDA: no
Description: treatment with Stick pack 30 ml containing PHGG 5 gr e Hyaluronic Acid 200 mg for 6 weeks
Study: NCT04203498
Drug: Nabiximols
Normalized name: Nabiximols
DrugBank: Nabiximols (DB14011)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nabiximols is a complex botanical medicine formulated from extracts of the cannabis plant that contains the principal cannabinoids delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) and also contains minor constituents, including other cannabinoid and non-cannabinoid plant components, such as terpenes, sterols, and triglycerides.Nabiximols will be self-administered by participants as an oromucosal spray in the morning and evening, up to a maximum of 12 sprays per day for 12 weeks.
Study: NCT05283278
Drug: Lactoferrin Bovine
Normalized name: lactoferrin, bovine
DrugBank: Lactoferrin (DB16555)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactoferrin granules (Pravotin®) in a dose of 100 mg /kg/day starting from birth to the 30th day of life for neonates in group A
Study: NCT01474083
Drug: GK1-399 (formerly TTP399)
Normalized name: Lor-253(former code)
DrugBank: APTO-253 (DB17143)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment A: GK1-399 200 mg. Oral administration, twice per day.
Study: NCT01474083
Drug: GK1-399 (formerly TTP399)
Normalized name: Lor-253(former code)
DrugBank: APTO-253 (DB17143)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment B: GK1-399 800 mg. Oral administration, once per day.
Study: NCT01474083
Drug: GK1-399 (formerly TTP399)
Normalized name: Lor-253(former code)
DrugBank: APTO-253 (DB17143)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment C: GK1-399 800 mg. Oral administration, twice per day.
Study: NCT01567930
Drug: Temsirolimus
Normalized name: Temsirolimus
DrugBank: Temsirolimus (DB06287)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intervention: Temsirolimus IV Eligible patients will receive temsirolimus IV on days 1,8,15 every 21 days. Treatment will continue till disease progression or untolerable side effects
Study: NCT04203797
Drug: dupilumab
Normalized name: Dupilumab
DrugBank: Dupilumab (DB12159)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pre-filled syringe administered by subcutaneous (SC) injections
Study: NCT02433457
Drug: CC-292
Normalized name: BTK inhibitor CC-292
DrugBank: Spebrutinib (DB11764)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02433457
Drug: Oral Omeprazole (OMP)
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01407822
Drug: Erlotinib
Normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In the neo-adjuvant treatment phase, erlotinib 150 mg/day taken orally for 6 weeks(42 days).In the post-surgery phase, erlotinib 150mg/day taken orally for 1 year or till disease progression or unacceptable toxicity.
Study: NCT01407822
Drug: Gemcitabine/cisplatin
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: In the neo-adjuvant treatment phase, patient will receive gemcitabine 1250mg/m2 IV on day 1 and day 8, and cisplatin 75mg/m2 on day 1 of a 3-week schedule for 2 cycles. In the post-surgery phase, Gemcitabine 1250mg/m2 IV on day 1 and day 8, and cisplatin 75mg/m2 on day 1 of a 3-week schedule for 2 cycles or till disease progression or unacceptable toxicity.
Study: NCT03844932
Drug: ST-0529
Normalized name: STS
DrugBank: Sodium tetradecyl sulfate (DB00464)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ST-0529 utilizes SmPill® technology to encapsulate the otherwise insoluble cyclosporine in a presolubilized, lipid-based formulation.
Study: NCT01235689
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The suggested regimen for participants initiating prednisone consisted of a maximum dose of prednisone 40 mg/day for 2 weeks, followed by a fixed taper for 6 weeks.
Study: NCT02481583
Drug: Levosulpiride
Normalized name: levosulpiride
DrugBank: Levosulpiride (DB16021)
Approvals — FDA: no, EMA: no, PMDA: no
Description: different formulations of levosulpiride
Study: NCT00119431
Drug: C1 inhibitor concentrate
Normalized name: C1 INHIBITOR
DrugBank: Human C1-esterase inhibitor (DB06404)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02195336
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 7.5mg/kg every 3 weeks for 3 cycles. Thereafter every 3 weeks until progression/relapse or unacceptable toxicity.
Study: NCT02195336
Drug: paclitaxel and carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Standard of care NSCLC first-line chemotherapy Every 3 weeks for 3 cycles. Doublets containing paclitaxel and carboplatin are preferred
Study: NCT01888757
Drug: Lamotrigine
Normalized name: Lamotrigine
DrugBank: Lamotrigine (DB00555)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lamotrigine Extended Release Tablets, 25mg, 50mg, 100mg, 200mg and 300 mg
Study: NCT02106507
Drug: apalutamide
Normalized name: Apalutamide
DrugBank: Apalutamide (DB11901)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: apalutamide, 240 mg/day, oral
Study: NCT02106507
Drug: Everolimus
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 5 mg/day of everolimus dose of everolimus will be escalated to 10 mg/day depending on the safety seen during dose escalation and steady-state trough drug levels as recommended
Study: NCT00098878
Drug: carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00881270
Drug: LACTIC ACID(ND)
DrugBank: Lactic acid (DB04398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dermacyd Infantile (LACTIC ACID)
Study: NCT02339766
Drug: Intrathecal Morphine
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrathecal Morphine 150 mcg will be co-administered with the spinal anesthetic.
Study: NCT00289601
Drug: eptifibatide
Normalized name: Eptifibatide
DrugBank: Eptifibatide (DB00063)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04069858
Drug: Switching to Generic Entecavir (Baracle®)
Normalized name: Entecavir
DrugBank: Entecavir (DB00442)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: switching to Baracle® 1 mg (generic drug) in chronic hepatitis B patients taking Baraclude® 1 mg (brand drug)
Study: NCT00612235
Drug: Lamotrigine
Normalized name: Lamotrigine
DrugBank: Lamotrigine (DB00555)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects had at least 3 months on a stable dosage of lamotrigine monotherapy.
Study: NCT00612235
Drug: Levetiracetam
Normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Subjects had at least 3 months on a stable dosage of levetiracetam monotherapy.
Study: NCT00612235
Drug: Carbamazepine
Normalized name: Carbamazepine
DrugBank: Carbamazepine (DB00564)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects had at least 3 months on a stable dosage of carbamazepine monotherapy.
Study: NCT01054508
Drug: nicotinic acid/laropiprant
DrugBank: Laropiprant (DB11629)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotinic acid/laropiprant (1g/20mg) daily for 4 weeks, then nicotinic acid/laropiprant (2g/40mg) daily for 8 weeks.
Study: NCT01141725
Drug: bendamustine hydrochloride
Normalized name: Bendamustine Hydrochloride
DrugBank: Bendamustine (DB06769)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01141725
Drug: idarubicin
Normalized name: Idarubicin
DrugBank: Idarubicin (DB01177)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT04049864
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lenalidomide is prescribed in a dose of 25 mg / day in a course of three weeks starting 7 days before the first vaccination course and ending on the day of the last vaccination course.
Study: NCT00662025
Drug: Sunitinib
Normalized name: Sunitinib
DrugBank: Sunitinib (DB01268)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sunitinib 37.5 mg daily, continuous dosing
Study: NCT00539877
Drug: irinotecan
Normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Postoperative day 1, IP CPT-11 chemotherapy will be given by CAPD catheter. CPT-11 in 1L of normal saline, prewarmed to 37°C will be given intraperitoneally.~If there is no DLT and patients agree with the treatment, patients can receive 3 more times of IP chemotherapy with same dose of CPT-11 at 3 weeks interval. After total 4 cycles of IP chemotherapy, peritoneal disease will be reassessed with abdominal-pelvis CT. Pharmacokinetic study is not planned with this treatment.
Study: NCT00528242
Drug: SLx-2101
Normalized name: SLx-2101
DrugBank: SLx-2101 (DB05615)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00246623
Drug: Exubera (inhaled insulin)
Normalized name: insulin human, rDNA origin Inhalation Powder [Exubera]
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00379457
Drug: carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00379457
Drug: etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00379457
Drug: ifosfamide
Normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00379457
Drug: topotecan hydrochloride
Normalized name: Topotecan Hydrochloride
DrugBank: Topotecan (DB01030)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00379457
Drug: vincristine sulfate
Normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00379457
Drug: vinorelbine tartrate
Normalized name: Vinorelbine Tartrate
DrugBank: Vinorelbine (DB00361)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00194740
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 60 mg/m2, IV, day 1 of each 21 day cycle
Study: NCT00194740
Drug: Vinorelbine
Normalized name: Vinorelbine
DrugBank: Vinorelbine (DB00361)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 27.5 mg/m2, IV, days 8 \& 15 of each 21 day cycle
Study: NCT00194740
Drug: Filgrastim
Normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 5 µg/kg/day s.c., to be administered days 2-21 of each cycle.
Study: NCT00930865
Drug: Dapagliflozin
Normalized name: Dapagliflozin
DrugBank: Dapagliflozin (DB06292)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tablets, Oral, 10 mg. Single Dose, 7 Days
Study: NCT03967249
Drug: IONIS GHR-LRx
Normalized name: IONIS-APOCIII-LRX
DrugBank: Olezarsen (DB18728)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive IONIS GHR-LRx by subcutaneous injection.
Study: NCT03967249
Drug: Somatostatin Receptor Ligand (SRL)
Normalized name: somatostatin
DrugBank: Somatostatin (DB09099)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive Somatostatin Receptor Ligand (lanreotide, octreotide) once monthly.
Study: NCT00670956
Drug: Betamethasone
Normalized name: Betamethasone
DrugBank: Betamethasone (DB00443)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 12 mg intramuscularly x 2 doses 24 hours apart
Study: NCT01601509
Drug: Nasal tramazoline with dexamethazone
Normalized name: dexamethasone / tramazoline Nasal Spray
DrugBank: Tramazoline (DB13064)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Every patient will undergo four assessments. Every assessment will consist of an overnight polysomnography with concomitant measurement of breathing route pattern (oral, nasal, oro-nasal breathing epochs) as previously described \[7\], along with a nasal resistance measurement. After baseline assessment and randomization patients of the first group will undergo a one-week therapy with nasal tramazoline and dexamethazone, while the patients of the second group will undergo a one-week therapy with nasal placebo (sodium chloride, 0.9% solution). The second assessment will take place at the end of this one week regimen. A washout period of two weeks will follow. Subsequently, the third assessment will take place and next the patients of the first group will undergo a one-week therapy with nasal placebo (sodium chloride, 0.9% solution), while the patients of the second group will undergo a one-week therapy with nasal tramazoline and dexamethazone. Fourth assessment will then follow.
Study: NCT00454636
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 80 mg/m2/day, intravenous (IV), every 3 weeks
Study: NCT00454636
Drug: Epirubicin
Normalized name: Epirubicin
DrugBank: Epirubicin (DB00445)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50 mg/m2/day, IV, every 3 weeks
Study: NCT00454636
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 60 mg/m2/day, IV, every 3 weeks
Study: NCT00454636
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 130 mg/m2/day, IV, every 3 weeks
Study: NCT00454636
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 60 mg/m2/day, IV, every 3 weeks
Study: NCT01229085
Drug: memotasone + salicylic acid
Normalized name: mometasone / salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: mometasone 0,1% + salicylic acid 5%.
Study: NCT00996671
Drug: GSK2256098
Normalized name: GSK2256098
DrugBank: GSK2256098 (DB16106)
Approvals — FDA: no, EMA: no, PMDA: no
Description: focal adhesion kinase inhibitor given as a single dose
Study: NCT04229849
Drug: Anrotenib plus Toripalimab
Normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anrotenib: 10 mg on day 1-14 orally repeated every 21 days; Toripalimab: 240 mg on day 1 intravenously repeated every 21 days.
Study: NCT04229849
Drug: Toripalimab
Normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Toripalimab: 240 mg on day 1 intravenously repeated every 21 days.
Study: NCT02451605
Drug: Analgesic nerve blockade (Ropivacaine)
Normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Analgesic nerve blockade (Ropivacaine) for total knee replacement surgery.
Study: NCT04514393
Drug: Ibrutinib
Normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral ibrutinib will be given at a dose of 560 mg daily and will be continued daily after completion of methotrexate and temozolomide.Ibrutinib is continued until disease progression, intolerable toxicity or death.
Study: NCT04514393
Drug: Temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral temozolomide will be given at 150mg/m2 from day1 to day 5 every 4 of all cycles，for up to 4 cycles.
Study: NCT00966953
Drug: Fluoride
Normalized name: Fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brush twice daily
Study: NCT00966953
Drug: Triclosan/Fluoride toothpaste
DrugBank: Triclosan (DB08604)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brush twice daily
Study: NCT00192608
Drug: saquinavir 500 formulation
Normalized name: saquinavir mesylate 500 MG
DrugBank: Saquinavir (DB01232)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: NRTIs + SQV/RTV 1000/100 mg BID using 200 mg SQV capsules switched at entry to ATV/SQV/RTV 300/1500/100 mg QD using 500 mg SQV tablet for 48 weeks with PK at days 0 and 8.
Study: NCT00192608
Drug: cross-over arm
Normalized name: Red Cross Canker Sore
DrugBank: Benzocaine (DB01086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: either ATV/SQV/RTV 300/1500/100 QD (500 mg SQV tabs) for 7 days then after PK SQV changed to 1600 mg QD (200 mg caps) with PK day 15, or ATV/SQV/RTV 300/1600/100 QD for 7 days with switch to SQV 1500 mg QD. After day 15 PK both groups switch to ATV/SQV/RTV 300/1500/100 QD to week 48
Study: NCT01369277
Drug: PF-04991532
Normalized name: PF-04991532
DrugBank: PF-04991532 (DB11765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose administration of PF-04991532 (100 mg, 300 mg and 750 mg) in tablet formulation under fasted condition.
Study: NCT01369277
Drug: PF-04991532
Normalized name: PF-04991532
DrugBank: PF-04991532 (DB11765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose administration of PF-04991532 (300 mg and 750 mg) in tablet formulation under fasted condition.
Study: NCT02029937
Drug: Proflavine, high resolution imaging
DrugBank: Proflavine (DB01123)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5-10 ml of proflavine hemisulfate (0.01%) will be sprayed on the esophageal mucosa. The HRME will then be inserted through the endoscope and gently placed against the mucosa. Imaging of abnormal tissues will be performed.
Study: NCT02101567
Drug: Oxytocin 5 IU iv infusion and Methtergine 0.2 mg iv
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In the second group of patients oxytocin 5 IU will be given iv infusion and Methergine 0.2 mg iv
Study: NCT00004497
Drug: UT-15
Normalized name: Polysilicone-15
DrugBank: Polysilicone-15 (DB11271)
Approvals — FDA: no, EMA: no, PMDA: no